"急性冠動脈症候群における経口P2Y12阻害剤の比較効果と安全性: ランダム化試験の52 816人の患者のネットワークメタ解析"に関する書簡に対するNavarese et alの回答
Eliano P Navarese1, Safi U Khan2, Stefan James3
1Interventional Cardiology and Cardiovascular Medicine Research, Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland (E.P.N.).
No abstract available in PubMed .
さらに関連する動画
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
06:04Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
関連する概念動画
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
